in the absence of a submission from the holder of the marketing authorisation:
mercaptamine (Cystadrops®) is not recommended for use within NHSScotland.
Indication under review: Treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice615KB (PDF)
- Medicine name:
- mercaptamine (Cystadrops)
- SMC ID:
Treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.
- Pharmaceutical company
- Recordati Pharmaceuticals
- BNF chapter
- Submission type
- Non submission
- Not recommended
- Date advice published
- 08 February 2021